Simrat Sohal - GlaxoSmithKline Pharmaceuticals Vice Compliance
| GLAXO Stock | 2,414 28.15 1.18% |
Executive
Simrat Sohal is Vice Compliance of GlaxoSmithKline Pharmaceuticals Limited
| Address | GSK House, Mumbai, India, 400030 |
| Phone | 91 22 2495 9595 |
| Web | https://india-pharma.gsk.com |
GlaxoSmithKline Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1709 % which means that it generated a profit of $0.1709 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4203 %, meaning that it generated $0.4203 on every $100 dollars invested by stockholders. GlaxoSmithKline Pharmaceuticals' management efficiency ratios could be used to measure how well GlaxoSmithKline Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, GlaxoSmithKline Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 29th of November 2024, Intangible Assets is likely to grow to about 405.7 M, while Total Assets are likely to drop about 32.2 B.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Francisco Canzano | Blue Coast Hotels | 47 | |
| Kapila Kandel | Blue Coast Hotels | 34 | |
| Gaganpreet Singh | Sumitomo Chemical India | 50 | |
| Gopalakrishnan | Sumitomo Chemical India | N/A | |
| Akshay Atri | Biofil Chemicals Pharmaceutical | 33 | |
| Smita Nanda | Kamat Hotels Limited | N/A | |
| Anisha Mangal | Biofil Chemicals Pharmaceutical | 28 | |
| P Mammen | Juniper Hotels | 62 | |
| Nikhil Singh | Kamat Hotels Limited | N/A | |
| Ashish BE | Sudarshan Chemical Industries | 54 | |
| Swati Poddar | JGCHEMICALS LIMITED | N/A | |
| Anil Nawal | Sumitomo Chemical India | 57 | |
| Pravin Desai | Sumitomo Chemical India | N/A | |
| Sreyas Arumbakkam | Oriental Hotels Limited | N/A | |
| Bhatia | Sudarshan Chemical Industries | N/A | |
| Rajdeep Barot | Juniper Hotels | N/A | |
| Abhisheeka Patro | Juniper Hotels | N/A | |
| Joseph Chacko | Biofil Chemicals Pharmaceutical | 63 | |
| Amey Athalye | Sudarshan Chemical Industries | N/A | |
| Mukul Gupta | Sudarshan Chemical Industries | 58 | |
| Shivalika Raje | Sudarshan Chemical Industries | N/A | |
Management Performance
| Return On Equity | 0.42 | ||||
| Return On Asset | 0.17 |
GlaxoSmithKline Pharmaceuticals Leadership Team
Elected by the shareholders, the GlaxoSmithKline Pharmaceuticals' board of directors comprises two types of representatives: GlaxoSmithKline Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlaxoSmithKline. The board's role is to monitor GlaxoSmithKline Pharmaceuticals' management team and ensure that shareholders' interests are well served. GlaxoSmithKline Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlaxoSmithKline Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amit Pandey, Executive Legal | ||
| Abhinav Kashyap, VP Technology | ||
| Chinmay Sharma, Executive Resources | ||
| Rashmi MD, Executive Medical | ||
| Ransom DSouza, Executive Affairs | ||
| Ajay Nadkarni, VP Secretary | ||
| Simrat Sohal, Vice Compliance | ||
| Sukanya Choudhary, Executive Affairs | ||
| Sougato Mitra, Head Specialty | ||
| Juby Chandy, WholeTime CFO | ||
| Shourov Mukherjee, Executive Vaccines | ||
| Bhushan Akshikar, MD Medicines | ||
| Aparajita Rajput, Vice Technology |
GlaxoSmithKline Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GlaxoSmithKline Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.42 | ||||
| Return On Asset | 0.17 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 382.29 B | ||||
| Shares Outstanding | 169.41 M | ||||
| Shares Owned By Insiders | 75.58 % | ||||
| Shares Owned By Institutions | 8.46 % | ||||
| Price To Book | 24.16 X | ||||
| Price To Sales | 11.48 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in GlaxoSmithKline Stock
GlaxoSmithKline Pharmaceuticals financial ratios help investors to determine whether GlaxoSmithKline Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GlaxoSmithKline with respect to the benefits of owning GlaxoSmithKline Pharmaceuticals security.